A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

NCT04071366 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytokine Release Syndrome

Interventions

DRUG: Itacitinib
DRUG: Immune effector cell therapy
DRUG: Placebo
BIOLOGICAL: Yescarta

Sponsor

Incyte Corporation